Business Description
Barinthus Biotherapeutics PLC
NAICS : 541713
SIC : 2833
ISIN : US91864C1071
Share Class Description:
STU:2AB: ADRTotal Employee Number:
14Description
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.98 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -0.23 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | -30 | |||||
3-Year Book Growth Rate | -34.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.54 | |||||
9-Day RSI | 46.39 | |||||
14-Day RSI | 48.82 | |||||
3-1 Month Momentum % | 15.96 | |||||
6-1 Month Momentum % | -4.39 | |||||
12-1 Month Momentum % | -29.68 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.05 | |||||
Quick Ratio | 6.05 | |||||
Cash Ratio | 5.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | 2.98 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -59.05 | |||||
ROA % | -45.8 | |||||
ROIC % | -169.76 | |||||
3-Year ROIIC % | 144.57 | |||||
ROC (Joel Greenblatt) % | -759.4 | |||||
ROCE % | -51.07 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.42 | |||||
Price-to-Tangible-Book | 0.52 | |||||
EV-to-EBIT | 0.51 | |||||
EV-to-EBITDA | 0.56 | |||||
EV-to-Forward-Revenue | 0.42 | |||||
EV-to-FCF | 0.74 | |||||
Price-to-GF-Value | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 0.59 | |||||
| Price-to-Net-Cash | 0.69 | |||||
Earnings Yield (Greenblatt) % | 194.42 | |||||
FCF Yield % | -132.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Barinthus Biotherapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.11 | ||
| Beta | -0.8564 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.37 | ||
| Volatility % | 82.42 | ||
| 14-Day RSI | 48.82 | ||
| 14-Day ATR (€) | 0.039503 | ||
| 20-Day SMA (€) | 0.575 | ||
| 12-1 Month Momentum % | -29.68 | ||
| 52-Week Range (€) | 0.428 - 1.6 | ||
| Shares Outstanding (Mil) | 40.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Barinthus Biotherapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Barinthus Biotherapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 37 days | ||
| General meeting for 2026 | 2026-07-02 09:30 | In 2 days | ||
| First quarter earnings results for 2026 | 2026-04-30 | 0.50 (+0.40%) | ||
| Annual report for 2025 | 2026-03-13 | 0.49 (+0.82%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-13 | 0.49 (+0.82%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 0.94 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-07 | 1.09 (-5.22%) | ||
| General meeting for 2025 | 2025-06-10 09:30 | 0.84 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-07 | 0.85 (+3.68%) |
Show
Entries
Barinthus Biotherapeutics PLC Frequently Asked Questions
What is Barinthus Biotherapeutics PLC(STU:2AB)'s stock price today?
The current price of STU:2AB is €0.56. The 52 week high of STU:2AB is €1.60 and 52 week low is €0.43.
When is next earnings date of Barinthus Biotherapeutics PLC(STU:2AB)?
The next earnings date of Barinthus Biotherapeutics PLC(STU:2AB) is 2026-08-07 Est..
Does Barinthus Biotherapeutics PLC(STU:2AB) pay dividends? If so, how much?
Barinthus Biotherapeutics PLC(STU:2AB) does not pay dividend.
Press Release
Articles on Barinthus Biotherapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers